Introduction
Bipolar affective disorder (BD) is a severe remittingrelapsing psychiatric disorder with an estimated lifetime risk of about 1%. The disorder is characterized by alternating episodes of mania and depression and there is a high financial and human cost. There is a strong hereditary component to BD but environmental factors also play a critical role in precipitating the disorder. No specific gene has yet been definitively linked to the disorder, although some chromosome regions such as 18p, 22q12 and Xq28 have been implicated by several studies. 1, 2 Thus, despite extensive research efforts, the underlying pathophysiology of BD remains unknown. Gene expression profiling using microarray technology has become a promising approach for the investigation of complex disorders, as the expression levels of thousands of genes can be assessed simultaneously. Expression-profiling studies of post-mortem brain tissue derived from patients who suffered from psychiatric disorders have already been published, with the majority reporting changes in the schizophrenia brain. [3] [4] [5] [6] [7] Others have investigated both schizophrenia and BD 8, 9 while a small number of studies have focused on BD. [10] [11] [12] [13] [14] [15] Recent work profiling dorsolateral prefrontal cortex (DLPFC) and hippocampal tissue from BD subjects has implicated several processes in the disorder including mitochondrial dysfunction, 8, 12, 14 oligodendrocyte and myelination changes, 9 apoptosis, 10 cell growth and development of the nervous system 11 and the ubiquitin-proteasome pathway.
transporters and stress reponse proteins have also been reported altered in BD. 13 However, it is not apparent how these diverse changes relate to each other and the underlying pathology. Furthermore, brain pH and/or agonal state have been shown to affect the expression of many mitochondrial, proteasome and apoptosis genes. 16 Here, we present results from a transcriptomics study of BD using tissue from the dorsolateral prefrontal cortex (DLPFC) and the orbitofrontal cortex (OFC). All samples were analysed using Affymetrix HG-U133A GeneChips, which comprise over 22 000 transcripts. The OFC has not previously been investigated in microarray studies of bipolar disorder and is thought to play a role in mood regulation and impulse control. 17 A wide range of patient demographic variables were examined as potential confounding factors and were considered in subsequent statistical analyses.
Materials and methods
Tissue collection and RNA extraction All procedures have previously been described. 18 In brief, fresh-frozen prefrontal cortex tissue from a total of 50 bipolar and 50 well-matched control individuals was obtained from the Neuropathology Consortium of the Stanley brain collection (Stanley Medical Research Institute, US). Each patient group consisted of 35 samples from the dorsolateral prefrontal cortex (Brodmann area 9) and 15 samples from the orbitofrontal cortex (Brodmann area 11). Separate cohorts were used for the two different brain regions. Key demographic and clinical characteristics of the samples used in the analysis are summarized in Table 1 . Total RNA was extracted from all samples using Tri-reagent (Sigma) or Trizol (Gibco-Brl). RNA quality for all samples was assessed using a high-resolution electrophoresis system (Agilent Technologies). 
Microarray analysis
Isolated total RNA was carried through the Affymetrix preparation protocol 19 and hybridized to HG-U133A GeneChips (Affymetrix). Affymetrix Microarray Suite 5 (MAS5) was used for image processing and data acquisition and the raw data were then subjected to our stringent quality control (QC) procedures. 18, 20 For the DLPFC, 30 bipolar and 31 control samples were included in the final analysis. For the OFC, 10 bipolar and 11 control samples were included in the final analysis. Expression measures were computed using the robust multi-chip average (RMA) method. 21 Finally, the gene expression matrix was filtered to exclude control probesets and to include only probesets that had a 'class A' assignment, that is, at least nine of its 11 probes overlapped the target transcript. This filtering step reduced the gene expression matrix to 19 537 probesets.
Detection of differentially expressed genes
Samples from the two brain regions were analysed separately. Analysis of covariance (ANCOVA) was used to identify differentially expressed genes while controlling for the effects of confounding variables. Briefly, a linear model was fitted for the expression of each probeset in order to partition the variability due to the disorder from the variability attributable to confounds, biological noise and experimental noise. A type III sums of squares ANCOVA was applied using the ssType3 function in S-Plus 6 (Insightful Corporation). P-values were adjusted using the Benjamini-Hochberg false discovery rate (FDR) controlling procedure 22 as implemented in the Bioconductor 23 package 'multtest'. 24 Quantitative variables that were significantly different between the disease and control groups and showed correlation with gene expression were considered as potential confounds. Drug treatment, brain pH and post-mortem interval (PMI) met these criteria in at least one brain region (Table 1) . PMI, in contrast to pH, does not influence mRNA levels greatly 25, 26 and was not included in the ANCOVA models to maximize the degrees of freedom.
For the DLPFC samples, the ANCOVA model fitted for each gene incorporated main effects for patient group (presence/absence of disorder), fluphenazine equivalents and brain pH. In a secondary analysis, a subset of 30 pH-matched samples (15 bipolar and 15 controls) were analysed as for the first model except for the exclusion of pH. For the OFC samples, the ANCOVA model fitted for each gene included a main effect for patient group and fluphenazine equivalents only. In a subsequent analysis, we used an ANCOVA model with main effects for patient group, fluphenazine equivalents and pH, for direct comparison to the DLPFC model.
Effects of other potential confounds
The potential effects of several variables that were not included in the ANCOVA analyses were assessed. The effect of PMI, drug abuse, alcohol abuse and lithium treatment on gene expression was examined for all genes found significantly altered in the OFC of bipolar patients compared to controls. Spearman's rank correlation test was used to assess the effect of PMI on gene expression as well as of drug and alcohol use, data for which was based on a qualitative rating scale (Table 1 ). Student's t-tests were performed to assess differences between lithium-treated (n = 3) and nonlithium-treated subjects (n = 18) for all differentially expressed genes.
Functional profiling of differentially expressed genes Functional profiling of differentially expressed genes was performed using GoSurfer. 27, 28 31 GoSurfer was used to identify GO categories specifically up-or downregulated in BD by submitting the lists of up-and downregulated transcripts simultaneously.
For comparison, functional profiling was then performed using Onto-Express. 32, 33 The list of differentially expressed genes was also inspected manually to confirm the output of the functional profiling tools and to identify other genes that may be relevant to bipolar disorder.
QPCR validation
For quantitative real-time PCR (QPCR), 3 mg of total RNA was treated with 6 U of DNase I (Roche) for 30 min at 371C and purified with RNeasy spin columns (Qiagen). Complementary DNA was synthesized from DNA-free RNA with an oligonucleotide deoxythymidine primer and Superscript First-Strand synthesis system (Invitrogen). Based on their functional categories, eight significant genes were selected for validation using TaqMan gene expression assays (Applied Biosystems). To avoid any potential DNA amplification that may have remained after DNase treatment, chosen QPCR assays spanned intron-exon boundaries. Additionally, the assays were designed to detect the same or very similar transcript populations measured by the corresponding significant microarray probeset. TFRC was chosen as an endogenous control for the normalization of all target genes as it had similar microarray expression levels to the target genes and was consistently expressed in microarray samples. There was no significant difference in the cycle threshold (C t ) values for TFRC between disease and control groups in either brain region (P = 0.11 (OFC); P = 0.48 (DLPFC)). Standard curves were constructed for each assay to ensure amplification efficiencies were close to 100% and comparable across all assays. QPCR was performed using the Applied Biosystems 1700 Expression Array System following manufacturer's instructions. The comparative C t method was employed for quantification of the transcript expression levels. 34 Triplicate delta C t values were generated for six assays and in duplicate for two; the median value in each case was used for subsequent analysis. Samples were removed from analysis if the standard deviation of replicates was > 1; 2
ÀDDC t values were then calculated and box-plots constructed for each sample group. Consistent outliers were investigated and four samples were removed from the OFC data set; two with poor cDNA profiles and two that failed our microarray QC procedures. One sample that failed QC was removed from the DLPFC data set. The mean expression of the two groups was compared using Student's t-test. A one-tailed test was performed on the OFC samples as a directional change was expected, and a two-tailed t-test was used for the DLPFC samples. The effects of drug treatment, brain pH, PMI, drug or alcohol abuse on the QPCR results was tested using Spearman's rank correlation test and the Benjamini-Hochberg FDR correction was applied.
Results
In the DLPFC, 30 bipolar disorder and 31 control samples (of an initial 35 in each group) passed our microarray QC procedures. After controlling for demographic variables found to influence gene expression (drug treatment and brain pH) and applying a false discovery rate correction, no significant changes were observed in the DLPFC. Repeat analysis on a pH-matched subset of 15 bipolar and 15 control DLPFC samples still did not reveal any significant differences. In the OFC, 10 bipolar and 11 control samples (of an initial 15 in each group) passed QC procedures. After correcting for drug treatment and false discovery, 393 transcripts were classified as differentially expressed (P < 0.05); 238 transcripts were upregulated in bipolar disorder and 155 were downregulated. A very similar set of changes (321/ 393) were identified in a subsequent analysis with pH included as a covariate in the ANCOVA model.
Gene expression changes in post-mortem brain tissue are usually modest (less than twofold) in studies of psychiatric disorders. 13, 35 In this study, one up-and 43 downregulated transcripts changed by more than 1.5-fold between disease and control groups. Three transcripts, synaptotagmin I (SYT1); ATPase, H þ transporting, lysosomal 70 kDa, V1 subunit A (ATP6V1A) and paternally expressed 3 (PEG3), were decreased by more than twofold.
Effects of other potential confounds PMI was significantly correlated with the expression of 10 of the 393 differentially expressed probesets in the OFC but none correlated with drug or alcohol abuse (Spearman's rank correlation test, corrected P < 0.05). Lithium treatment was a significant factor in the expression of one gene (CLASP2, corrected P = 0.04).
Pathway analysis
Pathway analysis using GoSurfer revealed four major GO categories (biological process branch) significantly altered in the OFC of bipolar patients (P < 0.01) (Figure 1 ). G-protein coupled receptor (GPCR) signalling and response to stimulus (in particular immune response) were significantly upregulated while intracellular transport and the ubiquitin cycle were downregulated. The same results were obtained using the option within GoSurfer to perform an FDR correction for simultaneous testing of multiple dependent GO categories. These pathways were also identified as the most over-represented in the differentially expressed transcript list using OntoExpress (data not shown).
Within the GPCR signalling pathway, 21 transcripts were upregulated in BD; 15 of these encoded receptors including the dopamine receptor D2 (DRD2) and serotonin receptor 7 (HTR7) ( Table 2) . Other upregulated GPCR transcripts of note included receptors for somatostatin (SSTR5), opioids (OPRM1 and OPRL1), arginine vasopressin (AVPR2), oxytocin (OXTR) and vasoactive intestinal peptide (VIPR2).
Twenty transcripts involved in immune response were upregulated in patients with bipolar disorder (Table 2) . These included six genes and receptors of the interleukin family, together with SOCS5, a regulatory protein associated with inflammatory processes and involved in suppressing cytokine signalling. Upregulation of azurocidin 1 (AZU1), a neutrophil-derived lysosome granule protein, could indicate increased numbers of circulating neutrophils. Other upregulated transcripts associated with the immune response included several complement cascade components (ORM2, PFC and C8A) and TNFRSF17, a tumour necrosis factor receptor family member associated with B-cell survival and autoimmunity.
Fifteen transcripts for genes involved in intracellular transport were decreased in the brains of subjects with bipolar disorder ( Table 2 ). Seven of these relate to the more specific process of nucleocytoplasmic transport. Nuclear import of proteins, vital for correct cellular targeting, is mediated by the karyopherin (importin) family of transport molecules; 36 karyopherin (importin) beta 1 (KPNB1) and importin 7 (IPO7) were downregulated at the transcript level. A highly significant downregulation of IPO7 was detected by two independent probesets (P = 0.00036 and P = 0.018) and the gene is located at 11p15, a region implicated in BD by a number of linkage and association studies. 37 Additionally, the transcript for RAN-binding protein 2 (RANBP2) showed a 1.6-fold reduction in the BD group and codes for a scaffolding protein where import/export complexes are assembled and disassembled.
Thirteen transcripts relating to the ubiquitin cycle were downregulated in bipolar disorder ( Table 2) . Three of these represent genes of the ubiquitinconjugating enzyme family (E2): ubiquitin-conjugating enzyme E2G 1 (UBE2G1); huntingtin interacting protein 2 (HIP2) and a hypothetical protein (FLJ11011) while six transcripts have ubiquitin protein ligase activity (WWP1, TRIM23, PJA2, PCGF4, HIP2 and VPS41). Another gene downregulated in BD was ubiquitin specific protease 14 (USP14), which encodes a deubiquitinating enzyme and maps to chromosome 18p11, a well-established susceptibility locus for both BD and schizophrenia. 38 Although not annotated with the GO term 'ubiquitin cycle', RAD23 homolog B (Saccharomyces cerevisiae) contains an N-terminal ubiquitin-like domain (Ubl) which interacts with the 26S proteasome; 39 the transcript for RAD23B was downregulated 1.4-fold in BD.
Other dysregulated transcripts of interest included synaptotagmin I (SYT1), a synaptic vesicle protein, which showed a 2.4-fold decrease in expression in BD (the largest change observed). Prolyl endopeptidaselike (PREPL) was decreased 1.7-fold in bipolar patients and a transcript for prolyl endopeptidase (PREP) itself showed decreased expression in the disease group but did not reach significance. Finally, the transcription factor cAMP responsive elementbinding protein 1 (CREB1) was also downregulated almost 1.5-fold.
QPCR validation
After correction for multiple testing, the downregulation of three genes examined by QPCR was confirmed in the OFC at a significance level of P < 0.05 (Table 3 and Figure 2 ) and a further two genes at P = 0.055.
Given the stringency of the multiple testing correction, it is likely that all five genes are differentially expressed in BD. The validated genes were PJA2, USP14, CREB1, PREPL and SYT1 and the fold changes obtained using data derived from microarray and QPCR investigations were comparable. However, we were unable to validate the upregulation of HTR7 Figure 1 Biological processes affected in the bipolar orbitofrontal cortex. Biological processes specifically enriched among the 238 upregulated transcripts and the 155 downregulated transcripts in bipolar disorder were identified and visualised using GoSurfer (http://biosun1.harvard.edu/complab/gosurfer/). In the hierarchical tree, the nodes represent individual GO biological process categories and the branches indicate the relationships between them. GO categories containing more than 12 genes are shown. Significantly altered processes (P < 0.01) are highlighted: red indicating specific upregulation of a GO category and blue indicating specific down-regulation of a GO category. Numbers refer to the GO category names listed below, which are divided into the four major pathways dysregulated in bipolar disorder. Note: the GO categories 'nuclear transport' and 'nucleocytoplasmic transport' were significant at P < 0.01 but are not shown as they contained less than 12 genes. Abbreviations: GPCR, G-protein coupled receptor; GO, gene ontology. by QPCR and DRD2 gave contradictory results. In agreement with the microarray data from the DLPFC, none of the transcripts in this brain region were significantly altered using QPCR (corrected P < 0.05). However, two ubiquitin-related genes showed a trend towards being significantly decreased in BD in the DLPFC (corrected P = 0.09). QPCR results were not affected by drug treatment, PMI, drug or alcohol abuse; however, one gene (PJA2) showed a moderate but significant correlation with brain pH (r = 0.63, corrected P = 0.03).
Discussion
The present microarray investigation showed that 393 transcripts were significantly altered in the OFC of bipolar patients compared to controls whilst, surprisingly, no significant changes were detected in the DLPFC. We considered whether the absence of significant changes in the DLPFC could be due to the samples being less well matched for demographic variables (mainly pH) compared to the sample set from the OFC. We therefore reanalysed a subset of 15 bipolar and 15 controls samples from the DLPFC that were well matched for pH, so this variable could be removed from the ANCOVA model. Still no differentially expressed genes were identified from the microarray data. We then considered the possibility that the additional covariate (pH) in the DLPFC model could be the reason that no significant changes were observed. When pH was included in the OFC analysis (i.e. the same covariates were used in the ANCOVA models for each brain region), changes between BD and controls were not eliminated. Indeed, a very similar set of transcripts was identified whether pH was included in the analysis of the OFC data or not. Therefore, the lack of changes in the DLPFC was not due to the inclusion of pH in the ANCOVA model for this brain region. This result also confirms that the differential expression of genes in the OFC was not confounded by pH. Our quality control procedures included two assessments of RNA quality, 18 neither of which revealed any differences between the OFC and DLPFC samples. It is therefore unlikely that the results in the two brain regions were affected by RNA quality.
One explanation for the lack of changes in the DLPFC is that this brain region is not severely affected in bipolar disorder. However, several studies have reported significant changes in the bipolar DLPFC 8, 9, [11] [12] [13] 15 and two ubiquitin-related genes showed a trend towards being downregulated in the DLPFC using the more sensitive QPCR technique (Table 3) . We also observed that the pattern of significant gene expression changes in the OFC was generally mirrored in the DLPFC, but fold changes were lower and differences were not significant. This may be due to the use of a different cohort, with different demographic and clinical characteristics, in which significant changes in gene expression were not detected with the statistical approach applied here. To establish whether the OFC is affected to a greater extent than the DLPFC in BD, a study using a single cohort is necessary for direct comparison of the two brain regions. Very few of the altered genes in the OFC were significantly correlated with other potential confounds PMI, drug abuse, alcohol abuse and lithium treatment while the ANCOVA model controlled for brain pH and drug treatment. Thus, it is unlikely that any of these factors affect the expression of the genes we have identified. A role for other variables that are difficult to quantify and assess statistically cannot be excluded but it is reasonable to suppose that the majority of the observed changes are disease-related.
The OFC has been prominently linked with affective disturbances in both major depression (MD) and BD. Imaging studies have shown a significant size reduction in the OFC of patients with MD 40 and BD patients have reduced activity in this brain region during both episodes of illness and in remission. 41, 42 Post-mortem studies on patients with MD have found a decreased density of neurons and glia in the OFC and DLPFC. 43 Interestingly, a recent cytoarchitectural study of the same OFC cohort studied here provided evidence for orbitofrontal pathology in BD and MD, but not in schizophrenia. 44 The OFC is thought to play a prominent role in emotional and social regulation, impulse control and mood whilst damage to the OFC does not affect cognition to a major extent. 17, 45 Thus, the functional attributes of the OFC correspond closely to the deficits and alterations that characterise the clinical presentation of BD.
The genes found to be differentially expressed in the OFC and the four major biological processes identified by pathway analysis relate to essential cellular processes.
Immune response Bipolar disorder has been associated with an activation of the immune response in a number of studies, Negative values indicate a decrease in expression in bipolar disorder. b P-values were calculated using two-tailed Student's t-test for microarray data and QPCR validation in the DLPFC. A onetailed t-test was used for QPCR validation in OFC as a directional change was expected. Corrected P < 0.05 is indicated with bold font. In the analysis of QPCR data, all genes were normalized to the endogenous control gene TFRC. Abbreviations: DLPFC, dorsolateral prefrontal cortex; OFC, orbitofrontal cortex; QPCR, quantitative real-time polymerase chain reaction; TFRC, transferrin receptor. Figure 2 Graphical plots of quantitative real-time PCR results for validated genes in the bipolar orbitofrontal cortex. All genes were normalized to the endogenous control gene TFRC. After correction for multiple testing, PREPL, CREB1 and SYT1 were significantly downregulated in bipolar disorder (P < 0.05) while USP14 and PJA2 were very close to significance (P = 0.055). Mean expression7 standard error of the mean is shown. Abbreviations: PREPL, prolyl endopeptidase-like; CREB1, cAMP responsive element binding protein 1; USP14, ubiquitin specific protease 14; SYT1, synaptotagmin 1; PJA2, praja 2, RING-H2 motif containing; TFRC, transferrin receptor.
although the specific nature of the response is unclear. 46, 47 CRIP1 has been shown to cause an imbalance in cytokine production in mice, favouring TH2 responses. 48 Together with upregulated transcripts for IL4R, IL4, IL5 and MS4A2 (b subunit of the high affinity IgE receptor), this suggests a skewing of helper T-cell responses to TH2 cytokine profile. This is normally associated with asthma and allergy and there is some evidence for comorbidity between these conditions and bipolar disorder. [49] [50] [51] There are also reports of mood symptoms in asthma patients, particularly during corticosteroid therapy; 52 however, it should be noted that lithium therapy is reported to modulate immune responses and affect asthma. 53 Interestingly, IL4 and IL5 lie within a susceptibility locus for BD on 5q31. Overall, these findings provide some support for an altered immune response in BD.
G-protein coupled receptor signalling pathway
The signalling and regulatory mechanisms of neurotransmitter systems, such as the monoamine system, rely largely on GPCRs. The monoamine system plays a crucial role in mood regulation and has been strongly linked to affective disorders including BD. 54 Additionally, antidepressants and most antipsychotic drugs are known to target this system; thus, the involvement of the dopaminergic and serotonergic systems in affective and psychotic disorders forms the basis of leading disease hypotheses. Our microarray analysis identified DRD2 and HTR7 as upregulated in BD but, due to a combination of low expression levels and complex expression patterns, we were unable to validate these changes using QPCR. Iwamoto et al. (2004) also investigated BD and found that changes to genes encoding receptors in the brain were especially difficult to validate using QPCR.
Two upregulated receptors, OPRM1 and SSTR5, have particular relevance to BD. Increased mRNA levels of OPRM1 in the brains of suicide victims suggest it may be involved in the aetiopathology of suicidal and depressive behaviours. 55 However, we did not find increased expression of OPRM1 in bipolar patients who died by suicide compared to those that died from other causes. Upregulation of somatostatin receptor 5 (SSTR5) is consistent with a report that this gene, located in the susceptibility region 16p13.3, is associated with the aetiology of BD. 56 Levels of somatostatin, which is known to modulate neuron excitability and the activity of neurotransmitters, 57 have been found altered in the CSF of BD patients. [57] [58] [59] Interestingly, SSTR5 can interact with DRD2 (also upregulated) to form a heterodimeric receptor with increased affinity for both dopamine and somatostatin. 60 Increased mRNA levels of both receptors may lead to an enhanced response to agonist binding with downstream effects on the cAMP signalling cascade.
In summary, increased expression of numerous cell surface receptors would affect the response to extracellular stimuli, including neurotransmitters. Downstream effects could include disturbances within second-messenger signalling cascades, eventually leading to altered transcription patterns. A number of studies report changes to G protein subunits in BD patients and there is strong evidence for abnormalities in signal transduction. [61] [62] [63] The common mood stabilizer, lithium, is known to act upon secondmessenger signalling pathways 64 but lithium treatment did not influence the genes we find altered in the GPCR signalling pathway. It is possible that the changes in GPCR signalling we observed are involved in the disease process and are normalized by lithium treatment. Thus, the role of GPCRs in BD warrants further study.
Intracellular transport
The consistent downregulation of intracellular transport genes, particularly those relating to nuclear import/export, suggests a possible impairment of this important process in BD. As well as influencing localization of nuclear proteins, this may affect the transport of proteins/mRNAs targeted to the synapse. Importins, which mediate the nuclear import of proteins, are also known to play a role in retrograde axonal transport, providing a mechanism for axonal injury signalling. 65 Ubiquitin cycle and synaptic genes Another important system found to be downregulated in bipolar disorder is the ubiquitin cycle. Its main role is to mark proteins for degradation by the proteasome through the attachment of a polyubiquitin chain (ubiquitination). This requires the sequential action of three families of enzymes: ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin ligases (E3). Decreased expression of these enzymes could impair targeting of substrates to the proteasome (and hence protein degradation/turnover) with widespread consequences.
By determining protein degradation, the ubiquitin cycle is involved in the regulation of numerous cellular processes including signal transduction, intracellular trafficking, endocytosis, regulation of transcription, immune response, DNA repair and neural activity. 66, 67 Thus, the ubiquitin cycle can influence the other pathways we find altered in BD.
The ubiquitin pathway is also implicated in a number of neurological diseases including Parkinson's disease, Angelman syndrome, Huntington's disease and Alzheimer's disease (AD). 68 It may be involved in the formation of protein aggregates in AD but such aggregates have not been reported in the bipolar post-mortem brain. Interestingly, mice homozygous for a mutation in the ubiquitin specific protease 14 gene (USP14) show defects in synaptic transmission but do not accumulate ubiquitin-positive protein aggregates or show neuronal loss. 69 Here, BD patients were found to have significantly lower levels of USP14 as detected by microarray analysis and validated by QPCR in the OFC. Coupled with the phenotype of USP14À/À mice and its location on 18p11 (one of the strongest linkage findings for BD to date), these results may implicate USP14 in the aetiology of BD.
A particularly relevant role for the ubiquitin cycle is in neuronal signalling: recycling and/or degradation of cell surface receptors and associated proteins via the endocytic pathway ensures signal termination. 70 Increasing evidence suggests that the ubiquitin pathway also plays an important role in synapse formation and function 67, 71, 72 and this is perhaps most relevant to the pathophysiology of BD. As well as reduced expression of genes involved in the ubiquitin cycle, four genes relating to synaptic transmission and synaptic plasticity were downregulated in bipolar patients. These were PJA2, SYT1, CREB1 and PREPL and all four were confirmed significantly decreased in BD using QPCR (Table 3) .
PJA2 is thought to be involved in sorting proteins to postsynaptic densities (PSD) and may play a significant role in synaptic communication and plasticity by regulating the formation of postsynaptic densities.
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SYT1 is a calcium sensor involved in triggering neurotransmitter release, 74 whose function is likely compromised by a 2.44-fold expression decrease in BD. The important transcription factor CREB1 is involved in regulating neuronal excitation, survival and synaptic plasticity. 75 Finally, PREPL is likely to function similarly to prolyl endopeptidase (PREP), which is thought to play a role in cortical functions 76 and in the maturation/degradation of neuropeptide signalling molecules. 77 Plasma concentrations of PREP are reported to be increased in mania and decreased in depression 78 while levels of some neuropeptides (substance P, somatostatin and vasopressin) are also reported altered in affective disorders. 57, 79 Interestingly, the common action of three mainstream mood stabilising drugs (lithium, sodium valproate and carbamazepine) on neurons was abolished by inhibiting PREP activity. 80 The efficacy of these mood stabilisers for treatment of BD may be due to modulation of the cAMP, PI and Wnt (wingless) signalling pathways to promote neuronal plasticity, 81 further implicating defects at the synapse in BD.
In summary, the consistent downregulation of genes relating to the ubiquitin cycle and the synapse may indicate a disturbance in synaptic function in BD. The validation of these changes by QPCR for five such genes further strengthens this notion.
Previous gene expression studies of bipolar disorder have identified several processes that may be disrupted in affected individuals. Recently, neuronal network perturbations were implicated in bipolar disorder pathology 11 and the results of the present study provide further evidence for synaptic dysfunction. A functional genomics approach to identify candidate genes and pathways for BD found similar changes including signal transduction, neurotransmitter and synaptic genes. 82 However, another microarray study of BD prefrontal cortex reported quite different categories of altered genes and, in contrast to our study, receptors were generally downregulated. 13 This could be explained by the investigation of different brain regions using different analysis methods. Despite these differences, significant changes in expression for two genes found altered in the DLPFC were reproduced here in the OFC: downregulation of solute carrier family 29 (nucleoside transporters), member 1 (SLC29A1) and upregulation of myelin transcription factor 1 (MYT1), which was detected by two independent probesets. MYT1 represents the only myelin-related gene significantly altered in BD in this study. We previously found a number of oligodendrocyte-related and myelination genes altered in BD and schizophrenia 9 but in BD most of these changes were detected with QPCR. The existence of disease subgroups and alternative splice variants may make it difficult to detect myelination changes using microarray technology. However, proteomics, NMR metabolomics and lipidomics studies in our laboratory confirm prominent white matter and lipid alterations in the BD brain (unpublished observations).
Mitochondrial dysfunction has been implicated in BD 83 although findings from microarray studies are inconsistent. Notably, two studies have reported mitochondrial changes in the same DLPFC cohort analysed here, in which we found no significant changes. Downregulation of the electron transport chain (ETC) and other mitochondrial genes was reported by Sun et al.
12 but a less stringent statistical analysis, with no multiple testing correction for example, could explain why significant results were obtained. The second study focused specifically on mitochondrial-related genes and concluded that although most changes were due to medication, a small number were disease-related. 8 Our analytical approach differed considerably as all transcripts on the HG-U133A chip were assessed to identify the most profoundly affected pathways in BD. Mitochondrial dysfunction was not among them, in agreement with other gene expression studies. 11, 13, 15 However, gene expression studies of the BD hippocampus also report downregulation of mitochondrial genes 14 as well as upregulation of apoptotic genes accompanied by downregulation of antioxidant genes 10 ; the potential link between oxidative stress induced by mitochondrial dysfunction and the latter findings was highlighted. Downregulation of mitochondrial genes is associated with lower brain pH 16 and it is possible that this factor contributes to some of the previous findings. However, as mitochondrial dysfunction has been reported by several independent microarray studies, its potential role in BD should not be excluded.
In addition to mitochondrial changes, numerous genes coding for subunits of the proteasome were downregulated in the bipolar hippocampus.
14 Our study revealed downregulation of a number of ubiquitin cycle genes and one proteasome subunit (PSMD12) in the OFC. These findings implicate the ubiquitin-proteasome pathway in BD but it is unclear why different elements of the pathway would be affected. Downregulation of the ubiquitin-proteasome pathway genes has also been observed in post-mortem tissue from schizophrenia 3, 4, 84, 85 and alcohol abuse patients. 86 In conclusion, this is the first transcriptomics study of bipolar disorder to identify numerous gene expression changes in the orbitofrontal cortex. Our results suggest that the OFC may be severely affected in BD, which corresponds well with the function of this brain region, particularly regarding emotional control. Using the same analytical approach, no changes were observed in the dorsolateral prefrontal cortex, perhaps due to different sources and/or degree of variation within the DLPFC cohort.
Four major biological pathways were affected in the OFC in the disease state. Downregulation of numerous genes involved in the ubiquitin cycle and with roles in synaptic transmission/plasticity may have significant and diverse effects on neurological function. Additionally, upregulation of a variety of receptors involved in transmitting neurotransmitter and neuropeptide signals may disturb synaptic transmission. Our results suggest that disruption of the ubiquitin pathway and synaptic genes may be prominently involved in the pathophysiology of bipolar disorder.
